IN2013MU03559A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MU03559A IN2013MU03559A IN3559MU2013A IN2013MU03559A IN 2013MU03559 A IN2013MU03559 A IN 2013MU03559A IN 3559MU2013 A IN3559MU2013 A IN 3559MU2013A IN 2013MU03559 A IN2013MU03559 A IN 2013MU03559A
- Authority
- IN
- India
- Prior art keywords
- gonadotropins
- fragmentation
- provides
- dose form
- aggregation
- Prior art date
Links
- 102000006771 Gonadotropins Human genes 0.000 abstract 4
- 108010086677 Gonadotropins Proteins 0.000 abstract 4
- 239000002622 gonadotropin Substances 0.000 abstract 4
- 229940094892 gonadotropins Drugs 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 230000002776 aggregation Effects 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 238000013467 fragmentation Methods 0.000 abstract 2
- 238000006062 fragmentation reaction Methods 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 238000005755 formation reaction Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14845007.5A EP3068374A1 (en) | 2013-11-12 | 2014-10-31 | Formulation for gonadotropins |
| PCT/IN2014/000691 WO2015075743A1 (en) | 2013-11-12 | 2014-10-31 | Formulation for gonadotropins |
| HK16111891.9A HK1223559A1 (zh) | 2013-11-12 | 2014-10-31 | 用於促性腺激素的配方 |
| AP2016009159A AP2016009159A0 (en) | 2013-11-12 | 2014-10-31 | Formulation for gonadotropins |
| KR1020167010341A KR101699677B1 (ko) | 2013-11-12 | 2014-10-31 | 고나도트로핀을 위한 제제 |
| US15/030,527 US20160250295A1 (en) | 2013-11-12 | 2014-10-31 | Formulation for gonadotropins |
| NZ718960A NZ718960A (en) | 2013-11-12 | 2014-10-31 | Formulation for gonadotropins |
| AU2014351326A AU2014351326B2 (en) | 2013-11-12 | 2014-10-31 | Formulation for gonadotropins |
| SG11201603142YA SG11201603142YA (en) | 2013-11-12 | 2014-10-31 | Formulation for gonadotropins |
| EA201690626A EA201690626A1 (ru) | 2013-11-12 | 2014-10-31 | Новый состав гонадотропинов |
| CA2928311A CA2928311A1 (en) | 2013-11-12 | 2014-10-31 | Formulation for gonadotropins |
| MX2016005154A MX356383B (es) | 2013-11-12 | 2014-10-31 | Formulación líquida de gonadotropina estabilizada con polietilenglicol. |
| JP2016525079A JP6166470B2 (ja) | 2013-11-12 | 2014-10-31 | ゴナドトロピンのための新規製剤 |
| IN3559MU2013 IN2013MU03559A (OSRAM) | 2013-11-12 | 2014-10-31 | |
| CN201480057647.6A CN105658201A (zh) | 2013-11-12 | 2014-10-31 | 促性腺激素的制剂 |
| TW103138047A TWI579003B (zh) | 2013-11-12 | 2014-11-03 | 促性腺激素之新穎調製劑 |
| ARP140104243A AR098386A1 (es) | 2013-11-12 | 2014-11-11 | Formulación para gonadotropinas |
| IL244986A IL244986A (en) | 2013-11-12 | 2016-04-07 | Formulation for gonadotropins |
| CL2016000944A CL2016000944A1 (es) | 2013-11-12 | 2016-04-20 | Nueva formulación de ganadotropinas |
| PH12016500738A PH12016500738A1 (en) | 2013-11-12 | 2016-04-20 | Formulation for gonadotropins |
| ZA2016/02718A ZA201602718B (en) | 2013-11-12 | 2016-04-20 | Formulation for gonadotropins |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3559MU2013 IN2013MU03559A (OSRAM) | 2013-11-12 | 2014-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013MU03559A true IN2013MU03559A (OSRAM) | 2015-07-24 |
Family
ID=52684607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3559MU2013 IN2013MU03559A (OSRAM) | 2013-11-12 | 2014-10-31 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20160250295A1 (OSRAM) |
| EP (1) | EP3068374A1 (OSRAM) |
| JP (1) | JP6166470B2 (OSRAM) |
| KR (1) | KR101699677B1 (OSRAM) |
| CN (1) | CN105658201A (OSRAM) |
| AP (1) | AP2016009159A0 (OSRAM) |
| AR (1) | AR098386A1 (OSRAM) |
| AU (1) | AU2014351326B2 (OSRAM) |
| CA (1) | CA2928311A1 (OSRAM) |
| CL (1) | CL2016000944A1 (OSRAM) |
| EA (1) | EA201690626A1 (OSRAM) |
| HK (1) | HK1223559A1 (OSRAM) |
| IL (1) | IL244986A (OSRAM) |
| IN (1) | IN2013MU03559A (OSRAM) |
| MX (1) | MX356383B (OSRAM) |
| NZ (1) | NZ718960A (OSRAM) |
| PH (1) | PH12016500738A1 (OSRAM) |
| SG (1) | SG11201603142YA (OSRAM) |
| TW (1) | TWI579003B (OSRAM) |
| WO (1) | WO2015075743A1 (OSRAM) |
| ZA (1) | ZA201602718B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2599031C1 (ru) * | 2015-08-11 | 2016-10-10 | Общество с ограниченной ответственностью "АйВиФарма" | Водная композиция рекомбинантного фолликулостимулирующего гормона человека (варианты) |
| GB201603280D0 (en) * | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| RU2633079C2 (ru) * | 2016-06-21 | 2017-10-11 | Федеральное государственное бюджетное научное учреждение "Центр экспериментальной эмбриологии и репродуктивных биотехнологий" (ФГБНУ ЦЭЭРБ) | Фармацевтическая композиция с пролонгированным действием гонадотропинов для проведения индукции суперовуляции у самок млекопитающих |
| CN112451652A (zh) * | 2020-12-07 | 2021-03-09 | 苏州智核生物医药科技有限公司 | 一种重组人促甲状腺素注射液 |
| CN115634284B (zh) * | 2022-10-31 | 2025-02-11 | 景泽生物医药(合肥)股份有限公司 | 一种促性腺激素冻干制剂及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW518235B (en) | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| IL140984A0 (en) * | 1998-07-23 | 2002-02-10 | Lilly Co Eli | Fsh and fsh variant formulations, products and methods |
| AU2004226666B9 (en) * | 2003-04-02 | 2010-04-08 | Ares Trading S.A. | Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant |
| KR101105871B1 (ko) | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| PT2049148T (pt) * | 2006-07-06 | 2016-12-30 | Daewoong Co Ltd | Formulação líquida estável da hormona do crescimento humana |
| US8329649B2 (en) * | 2008-11-04 | 2012-12-11 | Aska Pharmaceutical Co., Ltd. | Aqueous composition containing follicle-stimulating hormone and histidine |
| IT1395957B1 (it) * | 2009-05-19 | 2012-11-02 | Pharmaguida S R L | Uso di una combinazione di d-aspartato e l-aspartato per il trattamento della infertilita' maschile. |
| WO2011099036A2 (en) * | 2010-02-12 | 2011-08-18 | Intas Biopharmaceuticals Limited | Liquid formulation of follicle stimulating hormone |
| WO2011108010A2 (en) | 2010-03-05 | 2011-09-09 | Intas Biopharmaceuticals Limited | A thermostable liquid formulation of gonadotropins |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| US20130121961A1 (en) * | 2011-11-11 | 2013-05-16 | The Johns Hopkins University | Treatment modalities to prevent or treat loss of cardiovascular function in aging humans |
-
2014
- 2014-10-31 AP AP2016009159A patent/AP2016009159A0/en unknown
- 2014-10-31 JP JP2016525079A patent/JP6166470B2/ja not_active Expired - Fee Related
- 2014-10-31 KR KR1020167010341A patent/KR101699677B1/ko not_active Expired - Fee Related
- 2014-10-31 EP EP14845007.5A patent/EP3068374A1/en not_active Withdrawn
- 2014-10-31 SG SG11201603142YA patent/SG11201603142YA/en unknown
- 2014-10-31 MX MX2016005154A patent/MX356383B/es active IP Right Grant
- 2014-10-31 HK HK16111891.9A patent/HK1223559A1/zh unknown
- 2014-10-31 NZ NZ718960A patent/NZ718960A/en not_active IP Right Cessation
- 2014-10-31 CA CA2928311A patent/CA2928311A1/en not_active Abandoned
- 2014-10-31 WO PCT/IN2014/000691 patent/WO2015075743A1/en not_active Ceased
- 2014-10-31 US US15/030,527 patent/US20160250295A1/en not_active Abandoned
- 2014-10-31 IN IN3559MU2013 patent/IN2013MU03559A/en unknown
- 2014-10-31 EA EA201690626A patent/EA201690626A1/ru unknown
- 2014-10-31 AU AU2014351326A patent/AU2014351326B2/en not_active Expired - Fee Related
- 2014-10-31 CN CN201480057647.6A patent/CN105658201A/zh active Pending
- 2014-11-03 TW TW103138047A patent/TWI579003B/zh not_active IP Right Cessation
- 2014-11-11 AR ARP140104243A patent/AR098386A1/es unknown
-
2016
- 2016-04-07 IL IL244986A patent/IL244986A/en not_active IP Right Cessation
- 2016-04-20 PH PH12016500738A patent/PH12016500738A1/en unknown
- 2016-04-20 CL CL2016000944A patent/CL2016000944A1/es unknown
- 2016-04-20 ZA ZA2016/02718A patent/ZA201602718B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015075743A1 (en) | 2015-05-28 |
| AP2016009159A0 (en) | 2016-04-30 |
| CN105658201A (zh) | 2016-06-08 |
| KR20160048227A (ko) | 2016-05-03 |
| TW201529097A (zh) | 2015-08-01 |
| AR098386A1 (es) | 2016-05-26 |
| EP3068374A1 (en) | 2016-09-21 |
| JP2016534061A (ja) | 2016-11-04 |
| MX356383B (es) | 2018-05-24 |
| AU2014351326B2 (en) | 2017-08-31 |
| CA2928311A1 (en) | 2015-05-28 |
| CL2016000944A1 (es) | 2016-11-11 |
| TWI579003B (zh) | 2017-04-21 |
| SG11201603142YA (en) | 2016-05-30 |
| EA201690626A1 (ru) | 2016-09-30 |
| IL244986A0 (en) | 2016-05-31 |
| US20160250295A1 (en) | 2016-09-01 |
| KR101699677B1 (ko) | 2017-01-24 |
| HK1223559A1 (zh) | 2017-08-04 |
| ZA201602718B (en) | 2017-06-28 |
| JP6166470B2 (ja) | 2017-07-19 |
| PH12016500738A1 (en) | 2016-05-30 |
| IL244986A (en) | 2016-11-30 |
| NZ718960A (en) | 2017-06-30 |
| MX2016005154A (es) | 2016-08-17 |
| AU2014351326A1 (en) | 2016-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090919A1 (ru) | Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a | |
| MY172578A (en) | Oral dosing of glp-1 compounds | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| SG10201806539XA (en) | Liquid protein formulations containing ionic liquids | |
| PH12016500738A1 (en) | Formulation for gonadotropins | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| PH12018500690A1 (en) | Novel insulin analogs and use thereof | |
| MX2014004725A (es) | Formulaciones de etanercept estabilizadas con aminoacidos. | |
| NZ712270A (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
| MX2016004168A (es) | Formulaciones de efinaconazol estabilizadas. | |
| IN2014DN10386A (OSRAM) | ||
| NZ739588A (en) | Enhanced stability of novel liquid compositions | |
| EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| EA201591439A1 (ru) | Препараты полипептида фактора viii | |
| EA201590491A1 (ru) | Иммуногенная композиция | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
| PH12018501443A1 (en) | Methods of administering hepcidin | |
| EA201590061A1 (ru) | Фармацевтическая композиция | |
| MX2017016231A (es) | Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina. | |
| MX2015012720A (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. | |
| WO2018105941A3 (ko) | 탈모방지 또는 발모촉진용 주사용 조성물 | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита |